Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art ...
Jun 11, 2013
0
0
Trichloroethylene (TCE) exposure has possible links to increased liver cancer risk, and the relationship between TCE exposure and risks of cancers of low incidence and those with confounding by lifestyle and other factors ...
May 30, 2013
0
0
More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.
May 23, 2013
0
0
Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, a Mayo Clinic study has found. The overwhelming majority of patients with this aggressive lymphoma already have symptoms, ...
May 16, 2013
0
0
The number of teenagers and young adults dying from cancer in Britain has fallen from around 580 per year in the mid-70s (1975-77) to around 300 today (2008-2010), according to a new Cancer Research UK report.
Mar 25, 2013
0
0
The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex ...
Mar 3, 2013
0
0
Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics shows that in cancer, ...
Jan 10, 2013
0
0
Relatives of family members diagnosed with cancer are still at risk of the disease even if the diagnosis came at an older age, suggests a paper published on BMJ website today.
Dec 20, 2012
0
0
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.
Dec 14, 2012
0
0
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL ...
Dec 10, 2012
0
0
